The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets (including investment borrowings) in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. It is non-diversified.
Inception Date: 19/06/2006
Primary Benchmark: NYSE Arca Biotechnology TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.55%
Management Expense Ratio: 0.56 %
|EXEL||Exelixis Inc.||4.71 %|
|IONS||Ionis Pharmaceuticals Inc.||4.48 %|
|ICPT||Intercept Pharmaceuticals Inc.||3.87 %|
|ILMN||Illumina Inc.||3.75 %|
|AMGN||Amgen Inc.||3.72 %|
|INCY||Incyte Corporation||3.72 %|
|REGN||Regeneron Pharmaceuticals Inc.||3.67 %|
|VRTX||Vertex Pharmaceuticals Incorporated||3.62 %|
|XLV||SPDR Select Sector Fund - Heal..||0.13 %||
|VHT||Vanguard Health Care||0.10 %||
|XBI||SPDR Series Trust S&P Biotech||0.35 %||
|IHI||iShares U.S. Medical Devices||0.43 %||
|IYH||iShares U.S. Healthcare||0.43 %||
|FXH||First Trust Health Care AlphaD..||0.62 %||
|IXJ||iShares Global Healthcare||0.47 %||
|FHLC||Fidelity MSCI Health Care Inde..||0.08 %||
|IHF||iShares U.S. Health Care Provi..||0.43 %||
|HQH||Tekla Healthcare Investors||0.00 %||
|Market Performance vs.
|Market Performance vs. Exchange (NYSE Arca)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||24.90%||11%||F||25%||F|
|Risk Adjusted Return||64.28%||50%||F||66%||D|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.